D-1553 (Garsorasib), a Potent and Selective Inhibitor of KRASG12C in Patients With NSCLC: Phase 1 Study Results
Author:
Publisher
Elsevier BV
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference34 articles.
1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021
2. Non-small cell lung cancer: current treatment and future advances;Zappa;Transl Lung Cancer Res,2016
3. Diverse alterations associated with resistance to KRAS(G12C) inhibition;Zhao;Nature,2021
4. Personalized therapy for lung cancer: striking a moving target;Pakkala;JCI Insight,2018
5. Targeting the untargetable KRAS in cancer therapy;Liu;Acta Pharmacol Sin B,2019
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Recent advances of anti-angiogenic inhibitors targeting VEGF/VEGFR axis;Frontiers in Pharmacology;2024-01-04
2. From bench to bedside: current development and emerging trend of KRAS-targeted therapy;Acta Pharmacologica Sinica;2023-12-04
3. Nucleic Acid-Based Approaches to Tackle KRAS Mutant Cancers;International Journal of Molecular Sciences;2023-11-29
4. Targeted Therapies for Kirsten Rat Sarcoma (KRAS) G12C Mutant Metastatic Non-Small-Cell Lung Cancers;Cancers;2023-11-25
5. Efficacy and toxicity of drugs targeting KRAS G12C mutation in non-small cell lung cancer: a meta-analysis;Expert Review of Anticancer Therapy;2023-11-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"全球学者库"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前全球学者库共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2023 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3